To the Editor: In the study of zofenopril reported by Ambrosioni et al. (Jan. 12 issue),1 the subgroup analysis (their Table 5) showed beneficial effects in patients concomitantly treated with calcium-channel blockers during the six-week treatment period. During the observation period, significantly more patients in the zofenopril group (21.1 percent) than in the placebo group (15.9 percent) received calcium-channel blockers (P = 0.02, as shown in their Table 4). This difference raises the possibility that the favorable outcome in the zofenopril group may have been due in part to the calcium-channel blockers. Indeed, the administration of calcium-channel blockers after acute.
ASJC Scopus subject areas